Drug class
Neurokinin-1 (NK1) receptor antagonist prodrug; antiemetic
Mechanism of action
Fosaprepitant is converted to aprepitant, which selectively antagonises substance P at NK1 receptors in the central nervous system and gastrointestinal pathways involved in emesis.
General use cases
- Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin-based regimens, in combination with other antiemetics
- Prevention of nausea and vomiting associated with moderately emetogenic chemotherapy where covered by the specific product regimen
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
